August 2007 Briefing - HIV & AIDS
Here are what the editors at HealthDay consider to be the most important developments in HIV & AIDS for August 2007. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.
Repeat HIV Testing Improves Detection During Pregnancy
MONDAY, Aug. 27 (HealthDay News) -- Repeat testing for HIV during pregnancy increases opportunities for use of antiretroviral prophylaxis, particularly in high-prevalence areas in which women may seroconvert after an initial HIV-negative test, according to a report in the August issue of the American Journal of Obstetrics & Gynecology.
Central Nervous System HIV Triggers Early B-Cell Response
FRIDAY, Aug. 24 (HealthDay News) -- HIV infection of the central nervous system triggers a strong B-cell response, with the viral load correlating with the level of plasmablasts found in the cerebrospinal fluid, according to a study published online Aug. 15 in the Annals of Neurology.
Eye Cancer Risk Elevated in Kidney-Transplant Patients
THURSDAY, Aug. 16 (HealthDay News) -- Kidney-transplant patients have an increased risk of ocular squamous cell carcinoma, according to the results of a study published online Aug. 14 in the Journal of the National Cancer Institute. Because HIV patients also have an increased risk, the finding suggests that this malignancy is an immune deficiency-associated cancer.
FDA Approves Two HIV Drugs for Sale Outside the U.S.
TUESDAY, Aug. 14 (HealthDay News) -- Two medications targeting HIV infection, one of them for children, have gained tentative approval by the U.S. Food and Drug Administration for sale outside the United States.
HIV+ Women Have Higher Mortality Risk with Caesarean
THURSDAY, Aug. 9 (HealthDay News) -- HIV-infected women who undergo a Caesarean section are at higher risk of complications and have a higher risk of death than women without HIV, according to a report in the August issue of Obstetrics & Gynecology.
FDA Approves HIV Drug That Blocks CCR5 Receptor
TUESDAY, Aug. 7 (HealthDay News) -- The U.S. Food and Drug Administration has granted approval to Pfizer, Inc. to market the antiretroviral drug maraviroc, which will be sold under the trade name Selzentry. The drug is the first of a new class of drugs that combat the virus by blocking the CCR5 co-receptor on T cells.
U.S. Abstinence Programs Ineffective for HIV Prevention
FRIDAY, Aug. 3 (HealthDay News) -- Abstinence-only programs in the United States have no effect on the risk of HIV infection based on self-reported sexual behavior, according to a systematic review of 13 trials published online Aug. 3 in BMJ.